USPTO serial 97913613
BIOPORT
Reviewed by CopyMark Law Group
Status 733Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- LEE, DOUGLAS
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with BIOPORT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $749*
Plus Government fees of $900
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Julie Albert
Julie Albert BAKER BOTTS, L.L.P30 Rockefeller Plaza, 45th FloorNew York, NY 10112United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | New product commercialization services, namely, commercialization of pharmaceutical drugs, medical devices, and biotechnological products; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of hospitals, academic and research institutions, and biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; Promoting collaboration within the scientific, research, medical and pharmaceutical communities to achieve advances in the fields of medicine, health care, science and biomedical engineering for human performance; providing information on the topic of promoting public awareness of improving the performance of scientific, medical and pharmaceutical research by others to achieve advances in the fields of medicine, health care, science and biomedical engineering for human performance; promoting public awareness of the need for collaboration within the scientific, research, medical and pharmaceutical communities to achieve advances in the fields of medicine, health care, science and biomedical engineering for human performance; promoting public awareness of the need for the performance of scientific, medical and pharmaceutical research by others to achieve advances in the fields of medicine, health care, science, and biomedical engineering for human performance; but excluding from all of the foregoing the provision of medical services and the performance of clinical trials or clinical research; Providing business administration services for others | ACTIVE | — |
| 036 | Providing building management services for others | ACTIVE | — |
| 040 | Manufacturing services for others in the field of pharmaceutical drugs, medical devices, and biotechnological products; Custom manufacture of pharmaceuticals; manufacturing process consulting | ACTIVE | — |
| 042 | Contract research organization support services to the medical, health care, pharmaceutical, biotechnology, and medical device industries in the form of scientific and medical research services outsourced on a contract basis in the field of development of biopharmaceuticals and biologic assays; preclinical research, clinical research, and pharmacovigilance services in the nature of pharmacological research and analysis; Providing computer security services in the nature of administering digital certificates for others; Scientific and technological services, namely, scientific research, analysis, testing, in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences; scientific consultancy and research services for others in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences; technical consultancy for others in the field of computing and engineering; technological consultancy for others in the field of life sciences, physical sciences, and social sciences; technological research, development and design services in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences, namely, pharmaceutical drugs, medical devices, and biotechnological products; industrial design services; industrial research and technological research services in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences; scientific study and research in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences; industrial research in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences; academic technological research in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences; scientific research; computer programming services; computerized analysis of data, namely, data automation and collection service using proprietary software to evaluate, analyze and collect service data; technology analysis being technology consultancy services in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences; technological services, namely, data analysis in the field of computing and engineering; Technology specification, namely, analyzing technology requirements and developing recommendations for the computer software and systems and other technology needed to meet those requirements, in the fields of computing, life sciences, engineering, physical sciences, and social sciences; analysis of technical data by means of graphics, tables and reports in the field of computing and engineering; scientific analysis of technical data by means of graphics, tables and reports in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences; product evaluation services to assure compliance with industry standards; testing and analysis services of products in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences to assure compliance with industry standards; research laboratory analysis in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences; new product experimental design and failure analysis in the field of computing, life sciences, engineering and manufacturing, physical sciences, and social sciences; quality control services for others; providing temporary use of online non-downloadable software for accessing, analyzing, reading, and tracking information in the field of education, business development and scientific and industrial research; providing information, advisory and consultancy services in relation to scientific research and technology in the fields of computing, life sciences, engineering and manufacturing, physical sciences and social sciences; Research laboratory data analysis services in the field of pharmaceutical drug manufacturing | ACTIVE | — |
| 043 | Providing temporary housing accommodations for others | ACTIVE | — |
| 045 | Independent ethics committee review services, namely, reviewing standards and practice to ensure compliance with laws and regulations concerning the ethics of biomedical and medical research testing on human subjects; independent ethical review of biomedical research and medical research on human subjects to ensure compliance with ethics laws and regulations concerning the same; providing independent review of clinical trials involving human subjects, namely, reviewing research protocols and related information to ensure compliance with laws and regulations concerning the ethics of biomedical and medical research testing on human subjects; providing independent review of clinical trials involving human subjects, namely, reviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of research; Providing security guard services for others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Texas Medical Center
- Other trademarks owned by Texas Medical Center
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 043
- Other trademarks in Class 045
- Similar marks named BIOPORT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 14, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 13, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Oct 13, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Oct 13, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 23, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 22, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Apr 22, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Apr 22, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 21, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 20, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 20, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 20, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 3, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 24, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 24, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 24, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 12, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 17, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 17, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 28, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 9, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 2, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 2, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 2, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 2, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 29, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 29, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Apr 29, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jan 29, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 29, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 29, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 28, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 2, 2023 | NWAP | NEW APPLICATION ENTERED | — |